FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia.

ABSTRACT: Acute myeloid leukemia (AML) has a poor prognosis and high heterogeneity. Most cases of leukemias are caused by environmental factors interacting with the cell's genetic material, but treatment is still dominated by cell cycle drugs. Therefore, there is an urgent need to find reliable biomarkers. Based on the Gene Expression Omnibus database, Kaplan-Meier survival analysis and univariate Cox regression analysis were used to select the genes that had the most significant influence on the prognosis of patients with AML. Quantitative real-time PCR and Western blot were used to assess the effects of small interfering RNA transfection and lentiviral interference on the gene's knockout and overexpression, respectively. These method were also used to confirm the expression levels of the FHL1 gene

SUBMITTER: Luo B 

PROVIDER: S-EPMC11743414 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature